Approved for use through 08/31/2013, OMB 0651-0033 U.S. Patient and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number (Also Form PTO-1050

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

	Page	1	of	1
--	------	---	----	---

APPLICATION NO.: 08/078,768

ISSUE DATE October 23, 2007 INVENTOR(S) Richard H. Tullis

7,285,537 B1

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

## Title Page.

PATENT NO

Item (73) Assignee:

Delete "ISIS Pharmaceuticals, Inc., Carlsbad, CA (US)" and insert -- Molecular Biosystems, Inc., San Diego, CA (US) -.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Woodcock Washburn LLP 2929 Arch Street

Philadelphia, PA 19104

VA 22313-1450

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentialty is governed by 35 U.S.C. 122 and 37 CPR 114. This collection is estimated to take 10 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form ancitor suggestions for reducing this burden, should be sent to the Ohlef Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria,

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 33-579) requires that you be given certain information in connection with your submission of the attached tom related to a plant application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that; (1) the general authority for the collection of this information as 54 U.S.C. (2)(2); (2) furnishing of the information calcided is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark; and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark of this contribution or plant if I you do not furnish the requested information, the U.S. Patient and Trademark of Titles may not be able to absolute the principal purpose for the principal purpose

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U S C. 552) and the Privacy Act (5 U S C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended nursuant to 5.11 SC 5504mb.
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Procent Voranization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  A record from this system of records may be disclosed, as a routine use, to the Administrator.
  - General Servicos, or his-her designee, during an inspection of records conducted by GSA as part of that agency is responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA negulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application possisant to 3.9 (s. C.12(b)) or issuance of a patient pursuant to 3.9 (s. C.12(b)) or issuance of a patient pursuant to 3.9 (s. C.12(b)). The public of the record was feed in an application which became abandoned or in which the proceedings were terminated and which application is referred by the public of the record continuous conti
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or requisition.